nach oben

Calcified Tissue International

Erschienen in:

01.03.2005

Gender-Dependent Reductions in Vertebrae Length, Bone Mineral Density and Content by Doxorubicin Are Not Reduced by Dexrazoxane in Young Rats: Effect on Growth Plate and Intervertebral Discs

verfasst von: F. Mwale, J. Antoniou, S. Héon, N. Servant, C. Wang, G. M. Kirby, C. N. Demers, L. E. Chalifour

Erschienen in: Calcified Tissue International | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Doxorubicin (DOX) is widely used in anti-cancer cocktails. Dexrazoxane (DXR) is a cardioprotectant approved for use with DOX. The effect of DOX, with or without DXR, on bone in children is not well understood. The aim of this study was to examine the effect of DOX on vertebrae and femur length and bone density acquisition in young rats, as well as to test the hypothesis that young females are more susceptible to DOX-induced tissue damage than young males. The results of this study suggest that a single injection of DOX in young female and not male rats is associated with low bone turnover resulting in vertebrae and femur bone growth deficits. DOX selectively decreased BMD and BMC accrual in the lumbar verterbrae that was not prevented by DXR. DOX-treated rats also exhibited growth plate and intervertebral disc defects. This information will be useful in the design of interventions to promote bone growth or retard bone loss during DOX treatment.

Gertner, JM 1999Childhood and Adolescence. Primer on the Metabolic Bone Diseases and Disorder of Mineral Metabolism 4th edLippincolt Williams and WilkinsNew York4549Edited by MJ Flavus

Baroncelli, GI, Saggese, G 2000Critical ages and stages of puberty in the accumulation of spinal and femoral bone mass: the validity of bone mass measurementsHorm Res5428PubMed

Root, AW 2002Bone strength and the adolescentAdolesc Med135372PubMed

Ong, KK, Ahmed, ML, Dunger, DB 1999The role of leptin in human growth and pubertyActa Paediatr889598CrossRef

Leung, W, Hudson, MM, Strickland, DK, et al. 2000Late effects of treatment in survivors of childhood acute myeloid leukemiaJ Clin Oncol1832733279PubMed

Papadakis, V, Tan, C, Heller, G, Sklar, C 1996Growth and final height after treatment for childhood Hodgkin diseaseJ Pediatr Hematol Oncol18272276CrossRefPubMed

Haddy, TB, Mosher, RB, Reaman, GH 2001Osteoporosis in survivors of acute lymphoblastic leukemiaOncologist6278285CrossRefPubMed

Kaste, SC, Jones-Wallace, D, Rose, SR, et al. 2001Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their developmentLeukemia15728734CrossRefPubMed

Halton, JM, Atkinson, SA, Fraher, L, et al. 1996Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemiaJ Bone Miner Res1117741783PubMed

10.

Leeuwen, BL, Kamps, WA, Hartel, RM, et al. 2000Effect of single chemotherapeutic agents on the growing skeleton of the ratAnn Oncol1111211126CrossRefPubMed

11.

Shusterman, S, Meadows, AT 2000Long-term survivors of childhood leukemiaCurr Opin Hematol7217222CrossRefPubMed

12.

Rainsford, KD 1989Doxorubicin is a potent inhibitor of interleukin 1-induced cartilage proteoglycan resorption in vitroJ Pharm Pharmacol416063PubMed

13.

Friedlaender, GE, Tross, RB, Doganis, AC, et al. 1984Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat modelJ Bone Joint Surg Am66602607PubMed

14.

Young, DM, Fioravanti, JL, Olson, HM, Prieur, DJ 1975Chemical and morphologic alterations of rabbit bone induced by adriamycinCalcif Tissue Res184763PubMed

15.

Arola, OJ, Saraste, A, Pulkki, K, et al. 2000Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosisCancer Res6017891792PubMed

16.

Kumar, D, Kirshenbaum, LA, Li, T, Danelisen, I, Singal, PK 2001Apoptosis in adriamycin cardiomyopathy and its modulation by probucolAntioxid Redox Signal3135145CrossRefPubMed

17.

Green, DM, Grigoriev, YA, Nan, B, et al. 2001Congestive heart failure after treatment for Wilms’ tumor: a report from the National Wilms’ Tumor Study groupJ Clin Oncol1919261934PubMed

18.

Grenier, MA, Lipshultz, SE 1998Epidemiology of anthracycline cardiotoxicity in children and adultsSemin Oncol257285PubMed

19.

Krischer, JP, Epstein, S, Cuthbertson, DD, et al. 1997Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experienceJ Clin Oncol1515441552PubMed

20.

Frost, BM, Eksborg, S, Bjork, O, et al. 2002Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative studyMed Pediatr Oncol38329337CrossRefPubMed

21.

Kremer, LC, Dalen, EC, Offringa, M, et al. 2001Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up studyJ Clin Oncol19191196PubMed

22.

Kwok, JC, Richardson, DR 2000The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicityRedox Rep5317324CrossRefPubMed

23.

Bu’Lock, FA, Gabriel, HM, Oakhill, A, et al. 1993Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant diseaseBr Heart J70185188PubMed

24.

Schiavetti, A, Castello, MA, Versacci, P, et al. 1997Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary resultsPediatr Hematol Oncol14213222PubMed

25.

Wexler, LH, Andrich, MP, Venzon, D, et al. 1996Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicinJ Clin Oncol14362372PubMed

26.

Schuchter, LM Hensley, ML Meropol, NJ Winer, EP for the Americal Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel20022002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical OncologyJ Clin Oncol2028952903CrossRefPubMed

27.

Poole, AR, Laverty, S, Mwale, F (2000) “Endochondral Bone Formation and Development in the Axial and Appendicular Skeleton” In: Henderson, JE, Goltzman, D (editors), The Osteoporosis Primer, Cambridge University Press, United Kingdom, pp 3–17

28.

Ueda, Y 1987Problems in anti-leukemic drugs chemotherapy of childhood acute leukemiaNippon Ika Daigaku Zasshi54573580PubMed

29.

Héon, S, Bernier, M, Servant, N, et al. 2003Dexrazoxane does not protect against Doxorubicin-induced damage in the young ratAm J Physiol Heart Circ Physiol285499506

30.

Jahnukainen, K, Jahnukainen, T, Salmi, TT, et al. 2001Amifostine protects against early but not late toxic effects of doxorubicin in infant ratsCancer Res6164236427PubMed

31.

Rivier, C 1993Female rats release more corticosterone than males in response to alcohol: influence of circulating sex steroids and possible consequences for blood alcohol levelsAlcohol Clin Exp Res17854859PubMed

32.

Samuelsson, BO, Marky, I, Rosberg, S, Albertsson-Wikland, K 1997Growth and growth hormone secretion after treatment for childhood non-Hodgkin’s lymphomaMed Pediatr Oncol282734CrossRefPubMed

33.

Bradney, M, Karlsson, MK, Duan, Y, et al. 2000Heterogeneity in the growth of the axial and appendicular skeleton in boys: implications for the pathogenesis of bone fragility in menJ Bone Miner Res1518711878PubMed

34.

Hefferan, TE, Evans, GL, Lotinun, S, et al. 2003Effect of gender on bone turnover in adult rats during simulated weightlessnessJ Appl Physiol9517751780PubMed

35.

Pelker, RR, Friedlaender, GE, Panjabi, MM, et al. 1985Chemotherapy-induced alterations in the biomechanics of rat boneJ Orthop Res39195CrossRefPubMed

36.

Glackin, CA, Murray, EJ, Murray, SS 1992Doxorubicin inhibits differentiation and enhances expression of the helix-loop-helix genes Id and mTwi in mouse osteoblastic cellsBiochem Int286775PubMed

37.

Kohler, G, Shen, V, Peck, WA 1984Adriamycin inhibits PTH-mediated but not PGE2-mediated stimulation of cyclic AMP formation in isolated bone cellsCalcif Tissue Int36279284PubMed

38.

Ibanez, L, Potau, N, Ong, K, Dunger, DB, Zegher, F 2000Increased bone mineral density and serum leptin in non-obese girls with precocious pubarche: relation to low birthweight and hyperinsulinismHorm Res54192197CrossRefPubMed

39.

Qu, Q, Perala-Heape, M, Kapanen, A, et al. 1998Estrogen enhances differentiation of osteoblasts in mouse bone marrow cultureBone22201209CrossRefPubMed

40.

Samaan, NA, deAsis, DN,Jr., Buzdar, AU, Blumenschein, GR 1978Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapyCancer4120842087PubMed

41.

Turner, CH, Roeder, RK, Wieczorek, A, et al. 2001Variability in skeletal mass, structure, and biomechanical properties among inbred strains of ratsJ Bone Miner Res1615321539PubMed

42.

Colvin, JS, Bohne, BA, Harding, GW 1996Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3Nat Genet12390397CrossRefPubMed

43.

Wiseman, LR, Spencer, CM 1998Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapyDrugs56385403PubMed

44.

Seifert, CF, Nesser, ME, Thompson, DF 1994Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicityAnn Pharmacother2810631072PubMed

45.

Mandalunis, PM, Cabrini, RL, Ubios, AM 1997Iron overloading inhibits endochondral ossificationActa Odontol Latinoam105561PubMed

46.

Johanson, NA 1990Musculoskeletal problems in hemoglobinopathyOrthop Clin North Am21191198PubMed

47.

Tchetina, E, Mwale, F, Poole, AR 2003Distinct phases of coordinated early and late gene expression in growth plate chondrocytes in relationship to cell proliferation, matrix assembly, remodeling, and cell differentiationJ Bone Miner Res18844851PubMed

48.

Muller, I, Niethammer, D, Bruchelt, G 1998Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review)Int J Mol Med1491494PubMed

Titel: Gender-Dependent Reductions in Vertebrae Length, Bone Mineral Density and Content by Doxorubicin Are Not Reduced by Dexrazoxane in Young Rats: Effect on Growth Plate and Intervertebral Discs
verfasst von: F. Mwale
J. Antoniou
S. Héon
N. Servant
C. Wang
G. M. Kirby
C. N. Demers
L. E. Chalifour
Publikationsdatum: 01.03.2005
Verlag: Springer-Verlag
Erschienen in: Calcified Tissue International / Ausgabe 3/2005
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-004-0304-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2005

Study on Adsorption Mechanism of Proteins Onto Synthetic Calcium Hydroxyapatites Through Ionic Concentration Measurements

Bone Chemical Structure Response to Mechanical Stress Studied by High Pressure Raman Spectroscopy

Characterization of Circulating Human Osteoclast Progenitors: Development of In Vitro Resorption Assay

Reduced Fracture Risk in Users of Thiazide Diuretics

Vitamin D Analogs Versus Native Vitamin D in Preventing Bone Loss and Osteoporosis-Related Fractures: A Comparative Meta-analysis